

North Central Cancer Treatment Group

**N0871, A Phase II Study of Carboplatin (CBDCA), Paclitaxel (TAXOL), and Everolimus (RAD001)
in Previously Untreated Patients with Measurable Disease with
Cancer of Unknown Primary (CUP)**

Update 2 – November 12, 2010

Summary

Typographical errors have been corrected in the Dose Modification section of the protocol.

**Replacement pages are included. Please incorporate into the protocol
and keep this addendum with your protocol.**

Title Page Update 2 has been added and the NCI version date has been revised.

Section 8.0 **Dose Modification Based on Adverse Events**
Pages 28/30: Under the Non-hematologic section for Grade 3, the \geq symbol was inadvertently omitted.
This has now been corrected as follows:
 \geq Grade 3 (except hyperlipidemia*)